title: [Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].
abstract: The German Act on the Reform of the Market for Medicinal Products (AMNOG) will lead to rapid disappearance of many new psychotropic drugs from the market in Germany over the next few years or their not being introduced in the first place. This article lists the reasons and discusses possible solutions. In the long term, the AMNOG could not only lead to an improvement of psychopharmacology but also contribute to the development of psychiatry as a whole, especially if its standards become an international reference.
authors.affiliation: Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland. ggruender@ukaachen.de.
authors.forename: G
authors.initials: G
authors.lastname: Gründer
mesh_terms: D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000331:legislation & jurisprudence; D005858:Germany; D033161:Government Regulation; D018166:Health Care Reform / Q000191:economics / Q000331:legislation & jurisprudence*; D007880:Legislation, Drug; D008389:Marketing of Health Services / Q000191:economics / Q000331:legislation & jurisprudence*; D017063:Outcome Assessment, Health Care / Q000191:economics / Q000331:legislation & jurisprudence*; D011600:Psychopharmacology / Q000331:legislation & jurisprudence*; D011619:Psychotropic Drugs / Q000592:standards / Q000627:therapeutic use; D011785:Quality Assurance, Health Care / Q000191:economics / Q000331:legislation & jurisprudence*
chemical_list: D011619:Psychotropic Drugs
keywords: Benefit risk assessment; Clinical trial; Drug evaluation; Health technology assessment; Psychopharmacology